Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Salmeterol (50mcg) + Fluticasone Propionate (500 mcg)
Therapeutic Category
General and OTC medicines, Pulmonary, Respiratory, Asthma
Dosage Form
Capsule
Packaging Type
Capsules
Packaging
30
Price
₹625/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Flutialfa SF 500 Capsule combines two potent medications: Salmeterol (50mcg) and Fluticasone Propionate (500mcg), designed to help manage respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta-agonist (LABA) that works by relaxing the muscles around the airways, leading to their dilation and easing of breathing. Fluticasone Propionate is a corticosteroid that reduces inflammation in the airways, helping to prevent symptoms like wheezing, shortness of breath, and coughing, and preventing future asthma attacks.
Flutialfa SF 500 provides a combination of anti-inflammatory and bronchodilatory effects, offering both immediate relief and long-term prevention of respiratory symptoms. This capsule is beneficial for patients whose asthma or COPD is not adequately controlled with inhaled medications alone. It is typically used as part of a long-term management plan.
Common side effects include headache, throat irritation, hoarseness, oral thrush, or coughing. Serious side effects, though rare, may include chest pain, rapid heart rate, or signs of an allergic reaction like rash or swelling.
Flutialfa SF 500 Capsule is indicated for the maintenance treatment of asthma and COPD, helping to prevent bronchospasm and reduce airway inflammation.
Use under medical supervision, especially in patients with a history of heart disease, hypertension, or diabetes. Do not exceed the recommended dosage.
Store at room temperature, away from heat and moisture. Keep the capsules in a tightly closed container, and out of reach of children.
Composition : Salmeterol (50mcg) + Fluticasone Propionate (250mcg)
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Salmeterol (25mcg) + Fluticasone Propionate (500mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (250mcg)
Composition : Formoterol (12mcg) + Tiotropium (18mcg)
Composition : Formoterol (6mcg) + Budesonide (400mcg) Inhaler
Composition : Formoterol (6mcg) + Fluticasone Propionate (250mcg)
Composition : Doxofylline (400mg)
Composition : Doxofylline (650mg) SR
Composition : Doxofylline (400mg) + Montelukast (10mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This is a respiratory combination inhalation therapy used for the management of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting bronchodilator (LABA) that helps in long-term airway relaxation Fluticasone Propionate is an inhaled corticosteroid that reduces airway inflammation and swelling Together, they provide long-term control of asthma symptoms, prevention of exacerbations, and improved breathing capacity. It is a strong pulmonology and chronic respiratory care segment product.
Medical distributors and wholesalers can benefit from consistent long-term prescription demand from pulmonologists, chest physicians, and general practitioners. Asthma and COPD are chronic conditions requiring continuous therapy, ensuring regular monthly sales, strong prescription loyalty, and stable institutional demand.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in respiratory, pulmonology, and inhalation therapy segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high chronic disease demand, continuous refill prescriptions, and strong hospital + specialist-driven usage, making it a stable, high-value, and long-term pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in respiratory and inhalation formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the respiratory and chronic care segment.